GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (MEX:OPK) » Definitions » EV-to-EBIT

OPKO Health (MEX:OPK) EV-to-EBIT : 18.58 (As of May. 27, 2025)


View and export this data going back to 2011. Start your Free Trial

What is OPKO Health EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OPKO Health's Enterprise Value is MXN20,315 Mil. OPKO Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was MXN1,093 Mil. Therefore, OPKO Health's EV-to-EBIT for today is 18.58.

The historical rank and industry rank for OPKO Health's EV-to-EBIT or its related term are showing as below:

MEX:OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -140.54   Med: -6.98   Max: 670.72
Current: 19.31

During the past 13 years, the highest EV-to-EBIT of OPKO Health was 670.72. The lowest was -140.54. And the median was -6.98.

MEX:OPK's EV-to-EBIT is ranked better than
51.89% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.645 vs MEX:OPK: 19.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. OPKO Health's Enterprise Value for the quarter that ended in Mar. 2025 was MXN23,931 Mil. OPKO Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was MXN1,093 Mil. OPKO Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 4.57%.


OPKO Health EV-to-EBIT Historical Data

The historical data trend for OPKO Health's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health EV-to-EBIT Chart

OPKO Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.66 699.84 -2.95 -8.19 28.56

OPKO Health Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.07 -4.96 -13.83 28.56 21.43

Competitive Comparison of OPKO Health's EV-to-EBIT

For the Diagnostics & Research subindustry, OPKO Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OPKO Health's EV-to-EBIT falls into.


;
;

OPKO Health EV-to-EBIT Calculation

OPKO Health's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20314.575/1093.074
=18.58

OPKO Health's current Enterprise Value is MXN20,315 Mil.
OPKO Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,093 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health  (MEX:OPK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

OPKO Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=1093.074/23931.3443
=4.57 %

OPKO Health's Enterprise Value for the quarter that ended in Mar. 2025 was MXN23,931 Mil.
OPKO Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,093 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of OPKO Health's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.